An aqueous humor outflow device includes an arcuate scaffold that fits within a conventional aqueous humor outflow pathway of a mammalian eye to receive aqueous humor from a trabecular meshwork of the mammalian eye and allow flow of the aqueous humor through the arcuate scaffold to one or more collector channels that originate in a posterior wall of a Schlemm's canal. The arcuate scaffold includes a first arcuate rail, and a second arcuate rail spaced apart from, and substantially parallel to, the first arcuate rail. The first and second arcuate rails each have an anterior edge that is adjacent to the trabecular meshwork when inserted in the Schlemm's canal, and a posterior edge that is adjacent to the posterior wall of the Schlemm's canal. Structural components coupled to the first arcuate rail and the second arcuate rail maintain the respective anterior and posterior edges of the first and second arcuate rails spaced apart from, and substantially parallel to, each other.

Lacrimal implants for treating diseases or disorders are disclosed. More particularly, lacrimal implants, methods of making such implants, and methods of treating ocular, respiration, inner ear or other diseases or disorders using such implants are disclosed.

An atraumatic microsurgical forceps may include an actuation structure, an actuation sleeve having an actuation sleeve distal end and an actuation sleeve proximal end, a surgical blank, and atraumatic forceps jaws of the surgical blank having atraumatic forceps jaws distal ends and atraumatic forceps jaws proximal ends. The surgical blank may be disposed within the actuation sleeve wherein at least a portion of the atraumatic forceps jaws extends from the actuation sleeve distal end. A compression of the actuation structure may be configured to gradually extend the actuation sleeve over the atraumatic forceps jaws proximal ends. An extension of the actuation sleeve over the atraumatic forceps jaws proximal ends may be configured to gradually close the atraumatic forceps jaws wherein the atraumatic forceps jaws initially contact at the atraumatic forceps jaws distal ends.

Systems, devices, and methods for treating a glaucomatous eye are provided. Embodiments may provide a treatment probe for treating an eye of a patient. The treatment probe may have an elongate body with a contact surface at a distal end of the elongate body. A treatment fiber or light source may be housed in the treatment probe and may be configured to direct treatment energy from the contact surface. The contact surface may be configured to couple to a surface of the eye to deliver the energy into the target area. In many embodiments the contact surface may have a convex configuration with a rounded outer shape and edge that facilitates the sweeping of the probe surface across the eye during treatment delivery. In some embodiments the probe may be swept in arc motions while delivering treatment energy to the eye.

A method of modifying a refractive profile of an eye having an intraocular device implanted therein, wherein the method includes determining a corrected refractive profile for the eye based on an initial refractive profile, identifying one or more locations within the intraocular device based on the corrected refractive profile, and directing a pulsed laser beam at the locations to produce the corrected refractive profile. A system of modifying an intraocular device located within an eye, wherein the system includes a laser assembly and a controller coupled thereto. The laser assembly outputs a pulsed laser beam having a pulse width between 300 picoseconds and 10 femtoseconds. The controller directs the laser assembly to output the pulsed laser beam into the intraocular device. One or more slip zones are formed within the intraocular device in response thereto, and the slip zones are configured to modify a refractive profile of the intraocular device.

Implanting an intraocular shunt into an eye can involve creating an opening in the cornea and positioning a shunt in the anterior chamber of the eye such that the shunt terminates between layers of Tenon's capsule, thereby facilitating fluid flow out of the anterior chamber into a space between the layers of Tenon's capsule.

Disclosed is a surgical instrument for cataract eye surgery. The instrument generally includes a handpiece that delivers sub-ultrasonic and ultrasonic vibrations in either a continuous emulsification mode or with on-off pulses that dynamically drive a hollow needle in either a pulsed fragmentation mode or a pulsed emulsification mode. The pulsed fragmentation mode is efficient at cutting lens tissue and the pulsed emulsification mode is efficient in emulsifying the cut lens tissue. The pulsed modes manage heat buildup from becoming excessive in the eye during the cataract surgery. While in the pulsed fragmentation mode, the hollow needle is never given the chance to vibrate at an established resonant frequency of the handpiece due to the short on-off period. In contrast, the pulsed emulsification mode has a long enough on-off period to permit an ultrasonic resonant frequency in the handpiece to develop, which drives the hollow needle at a higher energy than the pulsed fragmentation mode.

A cannula ingress system may include a tip stabilization mechanism having a tip stabilization mechanism distal end and a tip stabilization mechanism proximal end, a fixation mechanism, a hypodermic tube having a hypodermic tube distal end and a hypos dermic tube proximal end, and a tip having a tip distal end and a tip proximal end. The tip may be disposed within the hypodermic tube wherein the tip distal end extends from the hypodermic tube distal end. The fixation mechanism may be disposed within a fixation mechanism channel of the tip stabilization mechanism. The tip stabilization mechanism may be disposed over the tip and the hypodermic tube distal end.

A cannula ingress system may include a tip stabilization mechanism having a tip stabilization mechanism distal end and a tip stabilization mechanism proximal end, a fixation mechanism, a hypodermic tube having a hypodermic tube distal end and a hypos dermic tube proximal end, and a tip having a tip distal end and a tip proximal end. The tip may be disposed within the hypodermic tube wherein the tip distal end extends from the hypodermic tube distal end. The fixation mechanism may be disposed within a fixation mechanism channel of the tip stabilization mechanism. The tip stabilization mechanism may be disposed over the tip and the hypodermic tube distal end.

A method of treating a subject with dry-form age-related macular degeneration (AMD) is disclosed. The method comprises administering into the subretina of the subject a therapeutically effective amount of a pharmaceutical composition comprising human RPE cells, wherein at least 95% of the cells thereof co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), wherein the trans-epithelial electrical resistance of the cells is greater than 100 ohms to the subject, thereby treating the subject.